. However, the likelihood of a high MVC was greater with large tumors (P = .05). The proportions of tumors with low and high MVC were 33% and 67%, respectively, if the tumor size was 2 cm or less, and 20% and 80%, respectively, if tumor size was larger than 2 an. There was no significant difference in the 20-year DFS as a function of tumor grade (P = .2). After combining patients with tumors of nuclear grades 2 and 3 compared with those of nuclear grade 1, the 20-year DFS was 93.9% (95% CI = 77J%-98.4%) for low MVC versus 66.9% (95% CI = 52.2%-78.0%) for high MVC (P = .02). In a multivariate analysis that included the variables tumor size, age, nuclear grade, estrogen receptor status, and MVC, only MVC appeared to be an independent prognostic indicator (P = .04). Conclusions: Angiogenesis as measured by MVC is a reliable independent prognostic marker of long-term survival in patients with node-negative breast cancer. The prognostic usefulness of this marker is maintained after more than 15 years of follow-up. A low MVC identifies a subgroup of patients with DFS of 92% or more, independent of tumor size or grade. [J Natl Cancer Inst 1996;88:
1764-9]
Breast cancers cause significant morbidity and mortality among women. Since distant metastases are the major cause of mortality, adjuvant systemic chemotherapy has been recommended in many patients, even those with small localized tumors. The large majority of these patients are cured with local therapy only, but despite small tumor size and no involved nodes, 20%-30% will develop distant disease {1-3). Chemotherapy has been used to benefit the small proportion of patients with node-negative breast cancer (NNBC) who may develop distant metastasis; because they cannot be identified, however, this treatment is applied to a much larger group, many of whom do not need such a treatment. For the individual patient, the decision to administer adjuvant chemotherapy is made on the basis of information from several prognostic markers, including tumor size, nodal status, nuclear and histologic grade, receptor status, ploidy, and proportion of cells in S phase; however, no single prognostic factor or combination of factors has been shown to reliably predict metastasis in an individual patient. The search for prognostic markers is important, both to identify those patients with occult metastases and to avoid chemotherapy in those patients whose tumors have not developed the opportunity for distant spread.
Weidner et al. (4) reported that angiogenesis can be measured by using immunohistochemical methods and correlated with the incidence of distant metastases and survival. Gasparini et al. (5) applied this to a series of patients with NNBC and confirmed the observation in this group. We were interested in further studying this in patients with NNBC who were followed for extended periods of time and who received no adjuvant therapy to see if we could find a marker adequate to identify women whose disease had not progressed sufficiently to require adjuvant chemotherapy.
This breast cancer database consists of patients with stage I-III disease who were treated with mastectomy at the University of Chicago Hospitals from 1927 through 1987 (2,6) and followed for a median of 15.4 years and a maximum of 35.8 years. From this database, we selected the group of patients with NNBC with small tumors who did not receive adjuvant radiation therapy, hormone therapy, or chemotherapy. The aim of the present investigation is to determine whether angiogenesis predicts clinical outcome in this group of patients and in the future to use angiogenesis as part of a panel of molecular markers that will serve as the basis to individually tailor the treatment decisions in women with small NNBC.
Methods

Patients and Disease-Free Survival
Of 2136 patients treated with mastectomy from 1927 through 1987 at the University of Chicago Hospitals, 848 were node negative, of whom 610 received no adjuvant chemotherapy, endocrine therapy, or radiation therapy. Sufficient archival material for study was obtained from 167 tumors. Clinical data and follow-up information were obtained from the medical records and were further complemented using telephone contacts with patients, family members, and physicians and from the tumor registry. Tumor size was determined by gross measurements of the excised lesion or by the largest tumor diameter as measured on a histologic section. Details of the patient population in this database have been published previously (2, 6) . The median follow-up period of all patients was 11.6 years, and the median follow-up period of living patients was 15.4 years (range, 2.6-35.8 years). To ensure that the patient group used for this study (167 patients) is representative of the entire group of patients with NNBC in the database who received no adjuvant therapy (610 patients) and to eliminate the possibility of inadvertent selection of a nonrepresentative group of patients, we compared the median follow-up period and the actuarial disease-free survival (DFS) between these two groups. The median follow-up period and the DFS of the two groups were not significantly different (/> = . 17 and P = 1.0, respectively). Patient characteristics arc shown in Table 1 . The patient ages ranged from 29 to 82 years (median age, 57 years).
Patients were censored at last follow-up if they were free of disease and were considered dead of disease if they were dead and were known to have recurrent disease at the last evaluation. DFS was defined as the elapsed time from mastectomy to disease recurrence or death. Death of disease or any recurrent disease, local or distant, was considered as an event in DFS calculation. Patients were censored for death due to intercurrent disease. Actuarial survival curves were calculated according to the Kaplan-Meier method (7).
Patient Material and Tumor Grading
To confirm the presence of sufficient tumor and ensure contemporary uniform grading, paraffin-embedded tissue blocks were sectioned, stained with hematoxylin-eosin, reviewed for the presence of tumor, and graded by a single pathologist (W. M. Recant) as outlined previously (8) . The tissue preservation was adequate for nuclear grading in 147 (88%) of the patients and histologic grading in 153(92%). (11) 14 (8) 39 (23) 86 (52) 28 (17) 148 (88) KD 18 (11) 24 (15) 96 (57) 27 (16) 20 (12) 11 (7) 78 (47) 64 (38) 14 (8) *Nuclear and histologic grading was performed by a single pathologist as described before by Fisher etal. (8) . |NA = not assessable.
Immunohistochemistry and Microvessel Count/Angiogenesis
From the block in which the tumor was confirmed and graded, 5-um sections mounted onto pretreated slides were dried in a 56 *C oven for 2 hours, then microwaved for 2 minutes at 725 W, deparaffinized, and rehydrated in graded alcohols and distilled water. The slides were rinsed with phosphate-buffered saline (PBS) and then incubated for 20 minutes at room temperature in 10% bovine serum albumin diluted in PBS. Subsequently, the slides were rinsed with PBS and incubated at 4 'C overnight with the primary antibody (monoclonal anti CD34/QB-END, Novocaslra Laboratories Ltd., Newcastle, U.K.) diluted 1:25 in PBS. After rinsing (three times, 5 minutes each) with PBS, the slides were incubated for 1 hour at room temperature with biotinylated rabbit anti-mouse immunoglobulin G (Vector BA-2000; Vector Laboratories, Inc., Burlingame, CA). After rinsing with PBS, endogenous peroxidase activity was quenched by placing the slides in a bath of 0.3% H 2 O 2 (Hydrox Laboratories, Elgin, IL) in PBS for 10 minutes at room temperature. The slides were rinsed with PBS and then incubated for 1 hour at room temperature with avidin-biotin-peroxidase complex (Vectastain Elite ABC, Vector PK-6100, Vector Laboratories, Inc.). The slides were again rinsed in PBS, developed with 3,3-diaminobenzidine (Sigma Chemical Co., St Louis, MO) chromogen solution (0.05% 33-diaminobenzidine in PBS and 0.006% H 2 O 2 ), dipped in 0.125% osmium tetroxide (Sigma Chemical Co.) to enhance positivity, counterstained with 1% methyl green (Trevigen Inc., Gaithersburg, MD), dehydrated in graded alcohol, air-dried, and mounted using Pro-Tex (American Scientific Product, McGraw Park, II) mounting medium under glass coverslips.
The quality of the staining was judged adequate using the staining of blood vessels in adjacent areas of normal breast tissue and muscle as an internal control. Vascularity was defined as previously described (9) by the number of vessels per field counted in the area of highest vascular density ("hot spots") at 400x magnification (0.1452 mm). The guidelines recommended by Gasparini and Harris (10) were followed. Single endothelial cells, endothelial cell clusters, and microvessels in the tumor, clearly separated from adjacent microvessels, were counted. Peritumoral vascularity and vasculanty in areas of necrosis were not scored. Branching structures were counted as a single vessel. The presence of lumen or erythrocytes in the lumen was not required to classify a structure as a vessel. If the vascularity was uniform, microvessels in three fields were counted and averaged. If the vascularity in different fields was not uniform, up to 10 fields were counted and the three highest counts were averaged. The microvessel count (MVC) was performed without the knowledge of the patients' outcome.
Microvessel Count Analyses
A cumulative probability distribution of tumors and MVC resulted in a sigmoid curve. The mean MVC was 22.4, with a standard deviation of 11.8 and a median of 20. We defined low MVC as less than 15 microvessels per 0.1452 mm as used by Gasparini et al. (5) and consistent with the results of Weidner et al. (9) (adjusting for differences in area counted). We found that this corresponds to the MVC of the 25th percentile of the tumors and appears to be an optimal cutoff because it is at the early poruon of the nse in the cumulative plot, and diere are sufficient subjects and events in each group. Thus, we defined the cutoff to be less than 15 microvessels/endothelial cells at 400x magnification. There are 46 patients in the low-MVC group and 121 in the high-MVC group.
Statistical Analyses
Actuarial survival curves were calculated according to the Kaplan-Meier method (7), and comparisons were made with the logrank test (//). For multivariate analysis, we used the Cox proportional hazards model (12) and a stepwise variable selection process (13) . The appropriateness of the proportiona] hazard assumption was confirmed with the use of standard graphical methods, and the chi-squared test was used for analysis of the distribution of prognostic factors. All P values were based on two-sided testing.
Results
Patient Survival and Microvessel Count/Angiogenesis
In the group of 167 node-negative patients who were treated only with mastectomy and no adjuvant therapy, the actuarial 20-year DFS was 74.8% (95% confidence
(95% CI = 56.8-78.0) in those with high MVC (P = .018). The actuarial 20-year overall survival was 40.8% (95% CI = 20.6-60.2) and 46.6% (95% CI = 35.8-56.7) (P = .90) and disease-specific survival was 92.4% (95% CI = 78.1-97.5) and 73.0% (95% CI = 62.5-81.1) (P = .04) in the patients with low-and high-MVC tumors, respectively. Fig. 1, A and B, shows the long-term outcome for patients as a function of the MVC for two different tumor size groups. For patients with tumors of 2 cm or less in size, the 20-year DFS was 93.3% (95% CI = 75.3-98.3) if the MVC was low and 67.8% (95% CI = 50.1-80.3) if it was high (P -.047; Fig. 1, A) . If patients had tumors larger than 2 cm (Fig. 1, B) , the 20-year DFS was 92.3% (95% CI = 56.6-98.9) and 70.9% (95% CI = 54.6-81.6) (P = .2) in the low-and high-MVC groups, respectively. Although a clear difference was seen, it did not reach statistical significance because a smaller percent of the tumors larger than 2 cm have low MVC and the numbers were not sufficient to reach significance. Interestingly, independent of tumor size, if the MVC was low, we observed similar excellent longterm survival. This is likely to occur if, as tumors grow and progress in the malignant cascade, they acquire the ability to form more microvessels and angiogenesis becomes a more important determinant of outcome than tumor size. And, consistent with this assumption, we demonstrate in Fig. 2 that larger size tumors are more likely to have high MVC. The percentage of patients with high MVC increased from 67% to 80% (P = .05) in tumors larger than 2 cm in size compared with those of 2 cm or less.
Tumor Size and Microvessel Count/Angiogenesis
Tumor Grade and Microvessel Count/Angiogenesis
There were no significant differences in outcome as a function of the nuclear grade. The 20-year DFS for nuclear grade 1, compared with grade 2 and 3, tumors was 91.0% (95% CI = 68.6-97.7) and 73.5% (95% CI = 61.2-82.4), respectively Fig. 1, C , in the combined group of patients who had high nuclear grade tumors, grades 2 and 3, the 20-year DFS was 93.9% (95% CI = 77.2-98.4) or 66.9% (95% CI = 52.2-78.0), respectively, if the MVC was low or high (P = .02), demonstrating that by using MVC one can select a favorable prognostic group, even among patients with higher grade tumors.
{P -.2). As shown in
Statistical Analyses
We performed univariate and multivariate analyses to identify the independent factors affecting DFS. Pathologic tumor size, age, nuclear grade, estrogen receptor status, and MVC were included in the model. The results are shown in Table 2 . MVC was a significant prognostic variable for DFS in both the univariate (P = .018) and the multivariate (P = .04) analysis. None of the other characteristics were significant in either the univariate or the multivariate analysis. The year of diagnosis was also analyzed in discrete categories before 1960 (n = 38), 1960-1969 (n = 24), 1970-1979 (n = 57), and 1980-1987 (n = 48), and was found to be not significant (P = .4, .8, and .6). The median MVC in these four periods is 20, 18, 19, and 20, respectively, and the percent of patients with low MVC is 22%, 28%, 27%, and 24%, respectively (P = 1.0).
Discussion
The majority of patients with NNBC who are receiving chemotherapy are likely to be overtreated because only 20%-30% would develop metastatic disease without this adjuvant treatment (1-3) . Unfortunately, the currently available prognostic markers are not satisfactory in identifying the patients who can be spared the treatment. The challenge is to develop new markers on the basis of evidence gathered about the molecular biology of breast cancer progression. Angiogenesis is necessary, both early and late in the malignant process. Growth of tumors beyond 1-2 mm 3 is dependent on angiogenesis, and tumor spread beyond the primary site is dependent on access to the vasculature (14) . The higher the count of the microvessels and the larger the surface area of these vessels, the higher the probability that tumor cells will enter the No. of patients at risk No. of patients at risk circulation (15) . Growth at a metastatic site is also dependent on new vessel growth, and angiogenesis may also be a marker of the acquisition of other characteristics needed for successful metastasis. Weidner et al. (4) have shown that angiogenesis can be quantified by counting microvessels that have been highlighted by immunohistochemical staining. They demonstrated a good correlation of microvessel density with distant metastases and survival in node-negative and node-positive patients with breast cancer. Gasparini et al. (5) reported that angiogenesis as measured by MVC was the strongest independent factor predicting relapse-free survival in 254 patients with NNBC, followed for a median of 62 months. None of their patients received adjuvant systemic therapy, but some had radiation therapy. Several other retrospective studies (9, (16) (17) (18) (19) (20) (21) have been published correlating MVC and outcome in breast cancer. These studies have low patient numbers, short follow-up, or patients receiving adjuvant therapy. Some investigators (22, 23) report no correlation between MVC and long-term outcome in breast cancer, raising some questions about the value of angiogenesis as a prognostic marker. Van Hoef et al. (22) studied a group of 93 patients with NNBC, followed for a median of 13 years, and found no correlation between neovascularization and relapse. There was no comment as to whether the patients had any treatments in addition to surgery. In the study by Axelsson et al. (23) , there were 110 patients with NNBC followed for a median of 11.5 years, some of whom received adjuvant chemotherapy or hormonal therapy.
Our study differs from previously published data in the maturity of the database (the last entry was made in 1987), in the length of follow-up (median, 15 years; maximum, 36 years), and in the absence of adjuvant therapy. Thus, it is possible to study the effects of angiogenesis on the unaltered natural history of the surgically treated breast cancer. We observed that the degree of angiogenesis as measured by the MVC within the tumor significantly correlates with long-term DFS. From the multivariate analysis, we found that the MVC determined immunohistochemically as anti-CD34 antigen positivity is a better predictor of DFS (Table 2 ) than is tumor size or nuclear grade. Patients whose tumors had a low MVC, irrespective of size or grade, had a greater than 92% DFS at 20 years. The MVC was less good at predicting those at high risk, since the 20-year DFS was still 65%-70% in those with a high MVC. We, as well as others (2, 24) , have previously reported on tumor size as an important prognostic factor for survival in breast cancer. Size was not a significant predictor of DFS in this analysis, probably because the majority of the patients in this group (88%) had tumors of 3 cm or less, and we did not have enough patients and events to demonstrate a difference between node-negative tumors of 2 cm or less in size and those of 2.1 -3 cm.
The scoring of angiogenesis using immunohistochemistry is not without pitfalls. Gasparini and Harris (25) and others (16, 23) have discussed in detail the plausible variables that influence the quantification of angiogenesis. The differences may result from variation in scoring, the selection of fields to be scored, the size of the field that is counted, and how many fields are counted. Variations may occur whether an average of several fields or the highest count is used. In most studies, antibody to factor VIII antigen was used. The expression of the von Willebrand factor on the tumor microvasculature may be variable, thus resulting in the variations observed when this antibody was used (26) . Recently, antibodies to CD31 and CD34 were found to give high-intensity reproducible staining of endothelial cells on paraffin sections (10, (27) (28) (29) . Other factors that may introduce a degree of variability and have to be controlled when counting the microvessels in tumors are areas of inflammation, fibrosis, and necrosis as well as vascularity in the stroma adjacent to the tumor, all of which need to be excluded from the scoring (16, 25) . Atten- .
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•Results of univariate analyses using the logrank test and multivariate analyses using the Cox proportional hazards model of prognostic factors for disease-free survival. A stepwise variable selection process was used, and the final model is shown. Only the microvessel count is a significant prognostic variable. CI = confidence interval.
tion also needs to be given to scoring individual vessels as well as vessel clusters and the counting of branching vessels. Despite these factors, MVC can be standardized. We believe that MVC as a prognostic marker will become more widely accepted and useful if the scoring criteria are simple and defined unambiguously. We counted endothelial cells and microvessels at 400x magnification, and from the analysis of the probability distribution, we chose the MVC at the 25th percentile as the cutoff to define low-and high-microvessel density. In our data, by dichotomizing the results of the MVC, we attempted to ultimately simplify the scoring so as to increase the future usefulness of the microvessel measurements.
In this study, the tumors were clinically detected and the majority were scored as highly vascular, even those less than 2 cm in diameter. The fact that high MVC occurs in small tumors suggests that the progression to high MVC often occurs early in the natural history of breast tumors; however, even among larger tumors, approximately 20% remain with low MVC. Angiogenesis appears to be necessary but not sufficient for tumor growth and generation of metastases, since in the node-negative patients the presence of areas of high MVC still permits a long-term DFS in approximately 70% of the patients. The onset of angiogenesis allows growth expansion only of tumor cell populations that are capable of proliferation, and it is permissive of metastases of those capable of invasion and seeding. Measuring intratumoral microvessel density in "hot spots" allows patients with NNBC to be stratified into relatively higher and lower risk subgroups. In our study, low intratumoral MVC identified a subgroup with a 93.1% (95% CI = 79.9-97.7) 20-year DFS, whereas high intratumoral MVC identified a subgroup with a 68.9% (95% CI = 56.8-78.0) 20-year DFS (P = .019 by univariate and P = .04 by multivariate analysis). Although we believe the 93.1 % survival is sufficient to suggest no adjuvant therapy for the smaller lower risk subgroup, the 68.9% survival of the larger higher risk subgroup would not justify adjuvant therapy in all these cases. We believe the higher risk subgroup needs to be further stratified, possibly by adding other useful prognostic factors. The ul-timate goal should be the development of a battery of markers, a tumor "fingerprint" that will predict the natural history of a patient's disease and will allow an individualized treatment plan.
